RandyF.SweisMD

PubMed

• A phase 1b open-label study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of py314 in combination with pembrolizumab in patients with ad...
  Kathryn E Beckermann, Amita Patnaik, Ira Winer, Winston Tan, Babar Bashir, Christos E Kyriakopoulos, Randy F Sweis, Marc Chamberlain, Brian I Rini> ;Investigational New Drugs. 2024 Apr 1
• A phase I trial of enzalutamide plus selective glucocorticoid receptor modulator relacorilant in patients with metastatic castration resistant prostate cancer.
  Kunal B Desai, Anthony V Serritella, Walter M Stadler, Peter H O'Donnell, Randy F Sweis, Russell Z Szmulewitz> ;Clinical Cancer Research. 2024 Mar 27
• NCCN Guidelines® Insights: Kidney Cancer, Version 2.2024.
  Robert J Motzer, Eric Jonasch, Neeraj Agarwal, Ajjai Alva, Hilary Bagshaw, Michael Baine, Kathryn Beckermann, Maria I Carlo, Toni K Choueiri, Brian A Costello, Ithaar ...> ;Journal of the National Comprehensive Cancer Network. 2024 Feb 1
• Bladder-Preserving Trimodality Therapy With Capecitabine.
  Connor Lynch, Randy F Sweis, Parth Modi, Piyush K Agarwal, Russell Z Szmulewitz, Walter M Stadler, Peter H O'Donnell, Stanley L Liauw, Sean P Pitroda> ;Clinical Genitourinary Cancer. 2024 Apr 1
• Dysregulated FGFR3 signaling alters the immune landscape in bladder cancer and presents therapeutic possibilities in an agent-based model.
  Daniel R Bergman, Yixuan Wang, Erica Trujillo, Anthony A Fernald, Lie Li, Trachette L Jackson, Alexander T Pearson, Randy F Sweis> ;Frontiers in Immunology. 2024 Jan 1
• 2 citations
  Melanoma and microbiota: Current understanding and future directions.
  Routy, B., Jackson, T., Mählmann, L., Baumgartner, C., Blaser, M., Byrd, A., Corvaia, N., Couts, K., Davar, D., Derosa, L., Hang, H., Hospers, G., Isaksen, M., Kroemer...> ;Cancer Cell. 2024 Jan 8
• 1 citations
  Mathematical model predicts tumor control patterns induced by fast and slow cytotoxic T lymphocyte killing mechanisms.
  Wang, Y., Bergman, D., Trujillo, E., Jackson, T., Pearson, A., Sweis, R.> ;Scientific Reports. 2023 Dec 18
• A Phase 2 Study of Sitravatinib in Combination with Nivolumab in Patients with Advanced or Metastatic Urothelial Carcinoma.
  Msaouel, P., Sweis, R., Bupathi, M., Heath, E., Goodman, O., Hoimes, C., Milowsky, M., Davis, N., Kalebasty, A., Picus, J., Shaffer, D., Mao, S., Adra, N., Yorio, J., ...> ;European Urology Oncology. 2023 Dec 16
• 16 citations
  The Development of STING Agonists and Emerging Results as a Cancer Immunotherapy.
  Jacobi B Hines, Alec J Kacew, Randy F Sweis> ;Current Oncology Reports. 2023 Mar 1
• 21 citations
  Combination of the STING Agonist MIW815 (ADU-S100) and PD-1 Inhibitor Spartalizumab in Advanced/Metastatic Solid Tumors or Lymphomas: An Open-Label, Multicenter, Phase...
  Funda Meric-Bernstam, Randy F Sweis, Stefan Kasper, Omid Hamid, Shailender Bhatia, Reinhard Dummer, Agostina Stradella, Georgina V Long, Anna Spreafico, Toshio Shimizu...> ;Clinical Cancer Research. 2023 Jan 4
• 5 citations
  A global method for fast simulations of molecular dynamics in multiscale agent-based models of biological tissues.
  Daniel Bergman, Randy F Sweis, Alexander T Pearson, Fereshteh Nazari, Trachette L Jackson> ;Iscience. 2022 Jun 17
• 15 citations
  Praluzatamab Ravtansine, a CD166-Targeting Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors: An Open-Label Phase I/II Trial.
  Valentina Boni, Mary J Fidler, Hendrik-Tobias Arkenau, Alexander Spira, Funda Meric-Bernstam, Nataliya Uboha, Rachel E Sanborn, Randy F Sweis, Patricia LoRusso, Misako...> ;Clinical Cancer Research. 2022 May 13
• 30 citations
  Hallmarks of Resistance to Immune-Checkpoint Inhibitors.
  Maria Karasarides, Alexandria P Cogdill, Paul B Robbins, Michaela Bowden, Elizabeth M Burton, Lisa H Butterfield, Alessandra Cesano, Christian Hammer, Cara L Haymaker,...> ;Cancer Immunology Research. 2022 Apr 1
• 2 citations
  Cost-Effectiveness of Immune Checkpoint Inhibitors in Urothelial Carcinoma-A Review.
  Arman S Walia, Randy F Sweis, Piyush K Agarwal, Andrew K Kader, Parth K Modi> ;Cancers. 2021 Dec 24
• 5 citations
  Severe COVID-19 infection is associated with aberrant cytokine production by infected lung epithelial cells rather than by systemic immune dysfunction.
  Thomas F. Gajewski, Sherin J. Rouhani, Jonathan A. Trujillo, Athalia Rachel Pyzer, Jovian Yu, Jessica Fessler, Alexandra Cabanov, Emily F. Higgs, Kyle R. Cron, Yuanyua...> ;Research Square. 2021 Nov 24
• 82 citations
  Phase I Dose-Escalation Trial of MIW815 (ADU-S100), an Intratumoral STING Agonist, in Patients With Advanced/Metastatic Solid Tumors or Lymphomas.
  Funda Meric-Bernstam, Randy F. Sweis, F. Stephen Hodi, Wells A. Messersmith, Robert H.I. Andtbacka, Matthew Ingham, Nancy Lewis, Xinhui Chen, Marc Pelletier, Xueying C...> ;Clinical Cancer Research. 2021 Oct 29
• 80 citations
  Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (Study 111/KEYNOTE-146): a phase 1b/2 study.
  Chung-Han Lee, Amishi Yogesh Shah, Drew W. Rasco, Arpit Rao, Matthew H. Taylor, Christopher Di Simone, James J. Hsieh, Alvaro Pinto, David R. Shaffer, Regina Gironés S...> ;The Lancet. Oncology. 2021 Jul 1
• 7 citations
  A validated mathematical model of FGFR3-mediated tumor growth reveals pathways to harness the benefits of combination targeted therapy and immunotherapy in bladder cancer
  Kamaldeen Okuneye, Daniel Bergman, Jeffrey Bloodworth, Alexander T. Pearson, Randy F. Sweis, Trachette L. Jackson> ;Computational and Systems Oncology. 2021 Jun 1
• 4 citations
  Multi-step screening of neoantigens' HLA- and TCR-interfaces improves prediction of survival.
  Guilhem Richard, Anne S. De Groot, Gary D. Steinberg, Tzintzuni Garcia, Alec Kacew, Matthew Ardito, William D. Martin, Gad Berdugo, Michael F. Princiotta, Arjun Vasant...> ;Scientific Reports. 2021 May 11
• 35 citations
  Wnt-β-catenin activation epigenetically reprograms Treg cells in inflammatory bowel disease and dysplastic progression.
  Jasmin Quandt, Stephen Arnovitz, Leila Haghi, Janine Woehlk, Azam Mohsin, Michael K. Okoreeh, Priya S. Mathur, Akinola Olumide Emmanuel, Abu Osman, Manisha Krishnan, S...> ;Nature Immunology. 2021 Mar 4
• 41 citations
  Germline genetic contribution to the immune landscape of cancer.
  Rosalyn W. Sayaman, Mohamad Saad, Vesteinn Thorsson, Donglei Hu, Wouter Hendrickx, Jessica Roelands, Eduard Porta-Pardo, Younes Mokrab, Farshad Farshidfar, Tomas Kirch...> ;Immunity. 2021 Feb 9
• 15 citations
  The Urinary Microbiome and Bladder Cancer: Susceptibility and Immune Responsiveness.
  Ciro Andolfi, Jeffrey Bloodworth, Apostolos Papachristos, Randy F. Sweis> ;Bladder Cancer. 2020 Sep 21
• 40 citations
  FGFR3 Alterations in the Era of Immunotherapy for Urothelial Bladder Cancer.
  Alec Kacew, Randy F. Sweis> ;Frontiers in Immunology. 2020 Nov 5
• 4 citations
  Morphological correlation of urinary bladder cancer molecular subtypes in radical cystectomies.
  Lisa Han, Alexander J. Gallan, Gary D. Steinberg, Randy F. Sweis, Gladell P. Paner> ;Human Pathology. 2020 Sep 26
• 2 citations
  Methods to assess anticancer immune responses in orthotopic bladder carcinomas.
  Randy F. Sweis> ;Methods in Enzymology. 2020 Jan 1
• Join now to see all

Journal Articles

• FGFR3 Alterations in the Era of Immunotherapy for Urothelial Bladder Cancer  
  Randy Sweis, MD, Frontiers in Immunology
• T Cell–Inflamed Versus Non-T Cell–Inflamed Tumors: A Conceptual Framework for Cancer Immunotherapy Drug Development and Combination Therapy Selection  
  Jason J. Luke, Randy F. Sweis, Clinical Cancer Research